CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 4, 2011, Pages 367-372

  Pulte, Dianne ^a,b   Furman, Richard R ^c   Broekman, M Johan ^a,c   Drosopoulos, Joan H F ^a,c   Ballard, Harold S ^a   Olson, Kim E ^a,c   Kizer, Jorge R ^c   Marcus, Aaron J ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CD39; Chronic lymphocytic leukemia; Prognosis; T lymphocyte

Indexed keywords

5' NUCLEOTIDASE; ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; APYRASE; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; PROGNOSIS; T LYMPHOCYTE SUBPOPULATION;

5'-NUCLEOTIDASE; ANTIGENS, CD; APYRASE; B-LYMPHOCYTES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; PROGNOSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 85047689068     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.005     Document Type: Article

References (22)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333:1052-7.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61 (4):212-36.
3. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-7. (Pubitemid 26189840)
4. Cukierman T, Gatt ME, Libster D, et al. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 2002; 43:1865-8. (Pubitemid 34874023)
5. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44:383-9. (Pubitemid 36118829)
6. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25. (Pubitemid 41291715)
7. Herrmann F, Lochner A, Philippen H, et al. Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol 1982; 49:157-62. (Pubitemid 12085209)
8. Kansas GS, Wood GS, Tedder TF. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J Immunol 1991; 146:2235-44.
9. Pound JD, Gordon J. Maintenance of human germinal center B cells in vitro. Blood 1997; 89:919-28. (Pubitemid 27121285)
10. Ingvarsson S, Dahlenborg K, Carlsson R, et al. Co-ligation of CD44 on naive human tonsillar B cells induces progression towards a germinal center phenotype. Int Immunol 1999; 11:739-44. (Pubitemid 29237765)
11. Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 2002; 8:358-65. (Pubitemid 34407030)
12. Langston HP, Ke Y, Gewirtz AT, et al. Secretion of IL-2 and IFN-gamma, but not IL-4, by antigen-specific T cells requires extracellular ATP. J Immunol 2003; 170:2962-70. (Pubitemid 36302168)
13. Hyman MC, Petrovic-Djergovic D, Visovatti SH, et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 2009; 119:1136-49.
14. Pulte ED, Broekman MJ, Olson KE, et al. CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb Res 2007; 121:309-17.
15. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-32. (Pubitemid 47281420)
16. Pulte D, Olson KE, Broekman MJ, et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.J Transl Med 2007; 5:23.
17. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signalling functions of lymphocyte CD73. Immunol Rev 1998; 161:95-109.
18. Rosi F, Tabucchi A, Carlucci F, et al. 5'-nucleotidase activity in lymphocytes from patients affected by B-cell chronic lymphocytic leukemia. Clin Biochem 1998; 31:269-72. (Pubitemid 28285359)
19. Beyer M, Schultze JL. Regulatory T-cells in cancer. Blood 2006; 108:804-9.
20. Dwyer KM, Deaglio S, Gao W, et al. CD39 and control of cellular immune responses. Purinergic Signal 2007; 3:171-80.
21. Gouttefangeas C, Mansur I, Schimd M, et al. The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8-positive cells. Eur J Immunol 1992; 22:2681-5.
22. Mackey JR, Galmarini CM, Graham KA, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and-insensitive populations. Blood 2005; 105:767-74. (Pubitemid 40070764)